

Publikationen 1999

Originalpublikationen in wissenschaftlichen Zeitschriften

1. Bachmann S, Caplazi P, Fischer M, Ehrensperger F, and Cone RW. Lack of association between Borna disease virus infection and neurological disorders among HIV-infected individuals. *Journal of NeuroVirology* 1999; 5, 190-195.
2. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, Telenti A, Vernazza PL, Bernasconi E, Sudre Ph, and the Swiss HIV Cohort Study. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?. *J Acquir Immune Defic Syndr* 1999; 21: 114-9.
3. Been-Tiktak AM, Boucher CA, Brun-Vezinet F, Joly V, Mulder JW, Jost J, Cooper DA, Moroni M, Gatell JM, Staszewski S, Colebunders R, Stewart GJ, Hawkins DA, Johnson MA, Parkin JM, Kennedy DH, Hoy JF, Borleffs JC. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. *Int-J-Antimicrob-Agents*. 1999; 11: 13-21.
4. Biderre C, Mathis A, Deplazes P, Weber R, Ackerstedt J, Méténier G, Vivares C. Molecular karyotype diversity in the microsporidian *Encephalitozoon cuniculi*. *Parasitology* 1999; 118: 439-445.
5. Breitenmoser A, Mathis A, Bürgi E, Weber R, Deplazes P. High prevalence of *Enterocytozoon bieneusi* in swine with four genotypes that differ from those identified in humans. *Parasitology* 1999; 118: 447-453.
6. Brown AJ, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. *J Infect Dis*. 1999; 180: 1043-9.
7. Chiesi A, Mocroft A, Dally LG, Miller V, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Arcieri R, Lundgren JD. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. *AIDS* 1999; 13: 2281-2288.
8. Ciernik J, Cone RW, Fehr, J, Weber R. Impaired liver function and retroviral activity are risk factors contributing to HIV-associated thrombocytopenia. *AIDS* 1999; 13: 1913-20.
9. Cone RW, Huang MLW, Corey L, Zeh J, Ashley R, Bowden R. HHV-6 Reactivation after Marrow Transplant. *J Infect Dis* 1999; 179:311-318
10. Evison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R. HIV-associated Non-Hodgkin lymphomas: Highly active antiretroviral therapy improves remission rate of chemotherapy. [Research Letter] *AIDS* 1999; 13: 732-734.
11. Fischer M, Huber W, Kallivroussis A, Ott P, Opravil M, Lüthy R, Weber R, Cone RW. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells and tissues. *J Clin Microbiol* 1999; 37:1260-1264.

12. Furrer HJ, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R, for the Swiss HIV Cohort Study. Discontinuation of Primary Prophylaxis against *Pneumocystis carinii* Pneumonia in HIV-1 Infected Adults Treated with Combination Antiretroviral Therapy. *N Engl J Med* 1999; 340: 1301-6.
13. Grob R, Zbinden R, Ruef C, Hackenthal M, Diesterweg I, Altwegg M, von Graevenitz A. Septicemia caused by dysgonic fermenter 3 in a severely immunocompromised patient and isolation of the same microorganism from a stool specimen. *J Clin Microbiol* 1999; 37: 1617-1618.
14. Günthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK: Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. *J Virol.* 1999; 73: 9404-12.
15. Günthard HF, Leigh Brown A, D'Aquila RT, Johnson V, Kuritzkes D, Richman D, Wong JK. Higher Selection Pressure from Antiretroviral Drugs in Vivo Results in Increased Evolutionary Distance in HIV-1 pol. *Virology.* 1999; 259:154-165.
16. Haefner M, Funke-Kissling P, Pfyffer GE, Lüthy R, Opravil M. Clarithromycin, rifabutin and clofazimine for treatment of disseminated *Mycobacterium avium* complex disease in AIDS patients. *Clin Drug Invest* 1999; 17: 171-178.
17. Harbarth, S, Ruef C, Francioli P, Widmer A, Pittet D. Nosocomial infections in Swiss university hospitals: a multi-centre survey and review of the published experience. *Schweiz Med Wochenschr.* 1999;129: 1521-1528.
18. HIV Trialists' Collaborative Group. Meta-analysis of the randomised evidence on zidovudine, didanosine and zalcitabine in the treatment of HIV infection. *Lancet* 1999; 353: 2014-2025.
19. Junghans C, Ledergerber B, Chan Ph, Weber R, Egger M for the Swiss HIV Cohort Study. Sex differences in HIV-1 viral load and progression to AIDS ? [Letter] *Lancet* 1999; 353:589.
20. Kaufmann P, Opravil M, Hauser M, Gaspert A, Laube I, Jenni R, Speich R. Die *Pseudomonas*-Pneumonie - eine wichtige Differentialdiagnose pulmonaler Infiltrate bei Aids. [Pseudomonas pneumonia: an important differential diagnosis of pulmonary infiltrates in AIDS] *SMW* 1999; 129: 120-130.
21. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer HJ, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Francioli P, Telenti A, for the Swiss HIV Cohort Study. AIDS opportunistic illnesses occurring after initiation of highly active antiretroviral therapy: The Swiss HIV Cohort Study. *JAMA [J Am Med Assoc]* 1999; 282: 2220-2226.
22. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer HJ, Francioli P, Weber R, for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Lancet* 1999; 353: 863-868.

23. Ledergerber B, Telenti A, Egger M for the Swiss HIV Cohort Study. HIV-related Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy: Prospective cohort study. *BMJ* 319: 23-24, 1999.
24. Leutenegger CM, Pusterla N, Mislin C, Weber R, Lutz H. Molecular evidence of ticks coinfecting with *Borrelia burgdorferi sensu lato* and the human granulocytic ehrlichiosis agent in Switzerland. *J Clin Microbiol* 1999; 37: 3390-3391.
25. Lorenzi P, Opravil M, Hirschel B, Chave J-P, Furrer H-J, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S and the Swiss HIV Cohort Study. Impact of drug resistance mutations on virologic response to salvage therapy. *AIDS* 1999;13: F17-F21.
26. Mathis A, Tanner I, Weber R, Deplazes P. Genetic and phenotypic intraspecific variation in the microsporidian *Encephalitozoon hellem*. *Int J Parasitol* 1999; 29: 767-770.
27. Morgan U, Xiao L, Sulaiman I, Weber R, Lal AA, Thompson A, Deplazes P. Which genotypes/species of *Cryptosporidium* are humans susceptible to? *J Eukaryot Microbiol* 1999; 46: 42S-43S.
28. Navin TR, Weber R, Rimland D, Roberts JM, Addiss DG, Wahlquist SP, Hogan SE, Vugia DJ, Juranek DD, Schwartz DA, Wilcox CM, Stewart JM, Thompson SE, Bryan RT. Declining CD4 T lymphocyte counts are associated with increasing likelihood of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. *J Acquired Immune Deficiency Syndromes* 1999; 20:154-159.
29. Opravil M, Hirschel B, Bucher HC, Lüthy R, and the Swiss HIV Cohort Study. A randomised trial of interferon- α 2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma. *Int J STD & AIDS* 1999; 10:369-375.
30. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Rued C, Zimmerli S. Incidence and predictors of virologic failure of antiretroviral triple drug therapy in a community based cohort. *AIDS Res Hum Retrov* 1999; 15: 1631-1638.
31. Pittet D, Harbarth S, Rued C, Francioli P, Sudre P, Pétignat C, Trampuz A, Widmer AF. Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. *Infect Control Hosp Epidemiol* 1999; 20:37-42.
32. Pfyffer GE, Funke-Kissling P, Rundler E, Weber R. Performance characteristics of the BDProbeTec system for direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens. *J Clin Microbiol* 1999; 37: 137-140.
33. Pusterla N, Leutenegger CM, Huder JB, Weber R, Braun U, Lutz H. Evidence of the Human Granulocytic Ehrlichiosis agent in *Ixodes ricinus* ticks in Switzerland. *J Clin Microbiol* 1999; 37: 1332-1334.
34. Raeber AJ, Sailer A, Hegyi I, Klein MA, Rulicke T, Fischer M, Brandner S, Aguzzi A, and Weissmann C. Ectopic expression of prion protein (PrP) in T

lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. *Proc.Natl.Acad.Sci.U.S.A.* 1999; 96, 3987-3992.

35. Rutishauser J, Funke G, Lütticken R, Ruef C. Streptococcal toxic shock syndrome in two patients infected by a colonized surgeon. *Infection* 1999;27:259-260.
36. Sax H, Ruef C, Widmer AF. Qualitätsstandard für Spitalhygiene an mittleren und grossen Spitälern der Schweiz: ein Konzeptvorschlag. *Schweiz Med Wochenschr.* 1999; 129: 276-284.
37. Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, Battegay M, Bucher HC, for the Swiss HIV Cohort Study: Cost effectiveness of azithromycin for preventing *Mycobacterium avium* complex infection in HIV positive patients in the era of highly active antiretroviral therapy. *J Antimicrob Chemother* 1999;44: 811-817.
38. Sudre P, Pfyffer GE, Bodmer T, Prod'hom G, Furrer HJ, Bassetti S, Bernasconi E, Matter L, Telenti A, Strässle A, Jacques JP, Weber R, and the Swiss HIV Cohort Study. Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: A country-wide 9-year cohort study. *Infection* 1999;27: 323-330.
39. Schüpbach J, Tomasik Z, Böni J, Nadal D, Flepp M, Ledergerber B, Opravil M, Cone R. Use of HIV-1 p24 as sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. *Proceedings of the Fourth European Conference on Experimental AIDS Research, EACAR'99, Tampere, Finland.* Monduzii Editore S.p.A. Bologna 1999: 157-162.
40. The Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. *AIDS* 1999; 13: 565-573.
41. Weber R, Christen L, Loy M, Schaller S, Christen S, Joyce CRB, Ledermann U, Ledergerber B, Cone R, Lüthy R, Cohen MR. Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals. *J Acquir Immune Defic Syndr* 1999; 22: 56-64.
42. Weber R, Ledergerber B, Zbinden R, Altwegg M, Pfyffer G, Spycher MA, Briner J, Opravil M, Meyenberger C, Flepp M, and the Swiss HIV Cohort Study. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: Prospective community-based cohort study. *Arch Intern Med* 1999; 159: 1473-1480.
43. Welzl-Hinterkörner E, Thölen H, Stürmer J, Opravil M, Bernauer W: Bilaterales zystoides Makulaödem nach erfolgreich therapiertem AIDS-assoziiertem CMV-Retinitis. *Ophthalmologie* 1999; 96: 87-91.
44. Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L and the Swiss HIV Cohort Study. Cell-associated HIV-1 RNA in blood as indicator of viral load in lymph nodes. *J Infect Dis* 1999; 180: 850-853.

45. Zinkernagel C, Ledergerber B, Battegay M, Cone RW, Vernazza P, Hirschel B, Opravil M, for the Swiss HIV Cohort Study. Quality of life in asymptomatic patients with early HIV-infection initiating antiretroviral therapy. [Letter] AIDS 1999; 13: 1587-1589
46. Originalpublikationen im Rahmen der Schweiz. HIV-Kohortenstudie oder anderer Studiengruppen
47. Bart PA, Meuwly JY, Corpataux JM, Yerly S, Rizzardi P, Fleury S, Munoz M, Knabenhans C, Welbon C, Pantaleo G, Meylan PR, and the Swiss HIV Cohort Study. Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. AIDS. 1999; 13: 1503-9.
48. Bürgisser P, Hammann C, Kaufmann D, Battegay M, Rutschmann OT, and the Swiss HIV Cohort Study. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. Clin Exp Immunol. 1999; 115: 458-63.
49. Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle V, Kunschak M, Engl W and the European Multinational IMMUNO AIDS Vaccine Study Group. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. AIDS 1999; 13: 1461-1468.
50. Ninet B, Rutschmann O, Burkhardt K, Metral C, Borisch B, Hirschel B, and the Swiss HIV Cohort Study. Detection of mycobacterial nucleic acids by polymerase chain reaction in fixed tissue specimens of patients with human immunodeficiency virus infection. Diagn Mol. Pathol. 1999; 8: 145-51.
51. Vanhems P, Lambert J, Guerra M, Hirschel B, Allard R, and the Swiss HIV cohort study. Association between the rate of CD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. J Infect Dis 1999; 180: 1803-8.

Übersichtsartikel

1. Allerberger F, Ruef C, Klare I, Witte W. Vancomycinresistente Enterokokken – Epidemiologie, klinische Bedeutung und praktische Hygienemassnahmen. Krh.-Hyg. + Inf.verh. 1999; 21: 35-39.
2. Flepp M, Jost J, Vernazza P, Bernasconi E, für die Subkommission Klinik [SKK] der Eidgenössischen Kommission für Aidsfragen [EKAF]. Präventionsempfehlungen zur Reduktion des HIV-Übertragungsrisikos bei orogenitalen Sexualpraktiken behalten ihre Gültigkeit. Bulletin des Bundesamtes für Gesundheit 1999; 11: 210-211 (15. März 1999).
3. Hirschel B, Opravil M: The year in review: antiretroviral treatment. AIDS 1999;13(suppl. A): S177-S187.
4. Nadal D, Weber R. Diagnose und Therapie der akuten Tonsillopharyngitis durch Gruppe A b-hämolsierende Streptokokken. (Teil 8). Schweiz. Ärztezeitung 1999;80:599-601.

5. Opravil M. Was ist die Evidenz für den kausalen Zusammenhang zwischen Antibiotika-Gebrauch und dem Auftreten von Resistenzen? (Teil 7) Schweiz. Ärztezeitung 1999; 80: 409-411.
6. Ruef C, Zbinden R. Wie werden Bakterien resistent gegen Antibiotika? (Teil 5). Schweizerische Aertzzeitung 1999; 80: 22-24.
7. Ruef C. (1999) Ist Impfen Privatsache? Schweiz Med Wochenschr. 1999; 129:495-498.
8. Ruef C, Redaktionskomitee Swiss-NOSO. Creutzfeldt-Jakob Krankheit (CJD) – wie gross ist das Risiko der Uebertragung während chirurgischen Eingriffen? Swiss-NOSO 1999; 6: 21-23.
9. Ruef C. Tuberculosis in Europe at the end of the second millennium. Infection 1999; 27: 311-312.
10. Telenti A, Munoz M, Bleiber G, Ledergerber B, Kaufmann D. Heterogeneity in the response to antiretroviral therapy. AIDS Rev 1999; 1: 147-155.
11. Weber R, Nadal D. Ist die Antibiotikaresistenz übertragbar? (Teil 6) Schweizerische Ärztezeitung 1999; 80: 198-200.

Bücher und Buchbeiträge

1. Ruef C. Intravenous Drug Abuse and Infection. Chapter 90 in: Clinical Infectious Diseases - A Practical Approach. Root RK, Waldvogel F, Corey L, Stamm WE (Editors); Oxford University Press, New York, Oxford. 1999; 849-852
2. Ruef C, Schaffner A. Infektionsprophylaxe. In: Kapitel ‚Infektionen‘ in ‚Innere Medizin‘. Georg Thieme Verlag, Stuttgart 1999; 1725-1738
3. Ruef C, Schaffner A. Infektionen des Zentralnervensystems. In: Kapitel ‚Infektionen‘ in ‚Innere Medizin‘. Georg Thieme Verlag. Stuttgart – New York. 1999; 1844-1853
4. Bryan RT, Weber R, Schwartz DA. Microsporidiosis, p.1840-1851 In: Guerrant RL, Walker DH, Weller PF (eds.) Tropical Infectious Diseases: Principles, Pathogens and Practice. Churchill Livingstone, Philadelphia 1999.
5. Schaffner A, Ruef C. Virale Infektionen. In: Kapitel ‚Infektionen‘ in ‚Innere Medizin‘. Georg Thieme Verlag. Stuttgart – New York. 1999; 1830-1843.
6. Schwartz DA, Weber R, Bryan RT. Microsporidiosis p. 625-643. In: Gilles (ed.) Protozoal Diseases. Arnold, London 1999.
7. Weber R. Epidemiologie und Diagnostik von Kryptosporidien, Mikrosporidien und Cyclospora, p. 267-274. In: Kirchner T, Lembcke B, Kist M (eds.) Ökosystem Darm VIII. Springer-Verlag Berlin 1999.
8. Weber R, Canning EU. Microsporidia, p. 1413-1420. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover RH (eds.) Manual of Clinical Microbiology. American Society for Microbiology, ASM Press, Washington D.C. 1999.

9. Weber R. Intestinal coccidia and microsporidia, p. 32.1-32.8. In: Armstrong D, Cohen J (eds.) *Infectious Diseases*. Mosby, London 1999.
10. Weber R, Schwartz D, Deplazes P. Laboratory diagnosis of microsporidiosis, p. 315-362. In: Wittner M (ed.) *The microsporidia and microsporidiosis*. American Society for Microbiology, ASM Press, Washington D.C. 1999.
11. Zimmerli W, Rief C. Antimikrobielle Therapie. In: Kapitel ‚Infektionen‘ in ‚Innere Medizin‘. Georg Thieme Verlag. Stuttgart – New York. 1999; 1750-1774